Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Payables (2016 - 2025)

Marimed has reported Payables over the past 15 years, most recently at $17.1 million for Q4 2025.

  • Quarterly Payables fell 6.42% to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.1 million through Dec 2025, down 6.42% year-over-year, with the annual reading at $17.1 million for FY2025, 6.42% down from the prior year.
  • Payables was $17.1 million for Q4 2025 at Marimed, up from $13.6 million in the prior quarter.
  • Over five years, Payables peaked at $18.8 million in Q1 2025 and troughed at $4.8 million in Q1 2023.
  • The 5-year median for Payables is $9.2 million (2023), against an average of $10.7 million.
  • Year-over-year, Payables tumbled 75.91% in 2021 and then soared 137.67% in 2024.
  • A 5-year view of Payables shows it stood at $6.5 million in 2021, then skyrocketed by 59.78% to $10.4 million in 2022, then dropped by 6.5% to $9.7 million in 2023, then skyrocketed by 88.35% to $18.3 million in 2024, then decreased by 6.42% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Payables are $17.1 million (Q4 2025), $13.6 million (Q3 2025), and $14.6 million (Q2 2025).